PSTV
Save the date
Plus Therapeutics is set to drop its Q1 numbers on May 29, 2026, which means the market’s favorite guessing game is back: can PSTV surprise, or will it be another tiny-revenue, big-loss kind of quarter?
The bar is pretty low
Analysts are looking for EPS of -$0.90 and revenue of $964.4K. That’s not exactly a “business is humming” setup. But in small-cap biotech, a low bar can be a gift — if the company can show progress on pipeline, financing runway, or commercial momentum, even a modest beat can matter.
Why you should care
The last quarter was a mixed bag: Plus Therapeutics posted $0.00 EPS, which beat estimates, but revenue of $1.37M still came in below the $1.84M target. Translation: this is still a company where every number gets judged like it’s trying out for the starting lineup.
Big picture
For investors, this upcoming report is less about whether Plus Therapeutics turns profitable tomorrow and more about whether it can keep the story moving forward without blowing up expectations. In other words: same biotech drama, new chapter.